enhance

Prontoblock and Mercantile Bank International Partner to Modernize the $1.25 Trillion Commercial Paper Market Through Tokenization

Source Node:
Time Stamp: August 10, 2023 7:39 AM - Modified On: August 10, 2023 - Published By:
Source Cluster:
Republished By Plato

New York, August 10, 2023 – Prontoblock, a leading digital asset fintech company, is pleased to announce its strategic partnership with Mercantile Bank International (MBI). This partnership aims to revolutionize the commercial paper market through the tokenization of these financial instruments. This partnership will empower MBI clientele to engage in the purchase and issuance of tokenized commercial paper using Prontoblock’s cutting-edge digital assets platform. Prontoblock will collaborate closely with issuers to identify the most suitable commercial paper instruments for tokenization. The outstanding value of U.S. commercial paper exceeded $1.25 trillion

Goverment Liason – Sandy

Source Node:
Time Stamp: August 9, 2023 5:37 AM - Modified On: August 9, 2023 - Published By:
Source Cluster:
Republished By Plato

Sandy Barsky Appointed as Government Liaison for the Blockchain & Infrastructure, the Rise of AI Conference. Washington, DC - [July 10, 2023] - The Government Blockchain Association (GBA) is thrilled to announce the appointment of Sandy Barsky as the Government Liaison for the upcoming Blockchain & Infrastructure, the Rise of AI Conference. The event is scheduled to take place on September 28-29, 2023, in Washington, DC. With an extensive background in the field, Sandy Barsky brings a wealth of experience to his new role. Having worked for decades at the

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:21 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating